Back to Search
Start Over
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: Prevent IV: A randomized controlled trial
- Source :
- JAMA, The Journal of the American Medical Association. Nov 16, 2005, Vol. 294 Issue 19, p2446, 9 p.
- Publication Year :
- 2005
-
Abstract
- The efficacy and safety of pretreating vein grafts is assessed with edifoligide for patients undergoing coronary artery bypass graft (CABG) surgery. Results reveal that while failure of at least 1 vein graft is quite common within 12 to 18 months after CABG surgery, edifoligide is no ore effective than placebo in preventing these events.
Details
- Language :
- English
- ISSN :
- 00987484
- Volume :
- 294
- Issue :
- 19
- Database :
- Gale General OneFile
- Journal :
- JAMA, The Journal of the American Medical Association
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.140194498